T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Procurement Category Manager - Fluid & Gas Distribution

Full-TimeUpdated
No salary listed
Senior
Bachelor's, MBA
Budapest, Hungary+1 moreMore locations: Brno, Czechia
Hybrid
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • A bachelor's degree is required.
  • At least 7 years of strategic procurement or category management experience in the Fluid & Gas Distribution space, including hands-on sourcing of valves and mass flow controllers, ideally in manufacturing, engineering, or industrial equipment.
  • Demonstrated success leading and managing complex categories and negotiating global agreements.
  • Experience working in a matrixed, international environment and collaborating across functions.
  • Experience managing long-tail spend and supplier rationalization, and working directly with Chinese suppliers and manufacturers within a global supply chain.
  • Strong analytical, financial, and problem-solving skills.
  • Proven success leading strategic sourcing initiatives that deliver measurable cost savings, risk reduction, and innovation.
  • Skilled negotiation and ability to influence and build relationships at all levels.
  • Strong proficiency in Excel and AI-enabled tools for data analysis, spend visibility, and sourcing decisions.
  • Excellent communication skills and ability to engage and influence top management, build business cases, and drive strategy through execution.
  • Knowledge of category management frameworks, supply market analysis, and cost modeling.
  • Ability to manage multiple priorities in a fast-paced, evolving environment.
  • Commitment to diversity, inclusion, and creating a positive team culture.
Responsibilities
  • Develop and execute the global Fluid & Gas Distribution (OEM) category strategy, aligned with divisional and enterprise priorities.
  • Build, lead, and maintain strategic supplier partnerships to enable innovation, supply assurance, and competitive advantage.
  • Lead global sourcing initiatives, including requests for proposals, contract negotiations, cost modeling, and supplier selection.
  • Analyze market intelligence, industry trends, and risk indicators to manage opportunities and vulnerabilities in the supply base.
  • Apply technical knowledge of valves and mass flow control equipment to guide supplier selection, specification alignment, and engineering discussions.
  • Manage long-tail spend by rationalizing low-volume suppliers and parts while maintaining supply continuity and driving efficiency.
  • Develop and manage relationships with Chinese suppliers, navigating regional sourcing dynamics, quality standards, and logistics to strengthen supply chain resilience.
  • Collaborate with Research and Development, Operations, Engineering, Quality, and Product Management to align sourcing actions with technical roadmaps and operational needs.
  • Drive continuous improvement in supplier performance through key performance indicator development, business reviews, and corrective action plans.
  • Advance sustainability, diversity, and responsible sourcing initiatives within the supplier ecosystem.
  • Use digital tools, data analytics, and automation to improve procurement processes and decision quality.
  • Serve as a business partner to internal stakeholders, communicating with senior and top management, building business cases, and translating strategy into execution to support long-term strategic planning.
Desired Qualifications
  • An MBA or advanced degree in Supply Chain, Business, Engineering, or a related field is preferred.
  • Familiarity with chromatography instrumentation is a plus.
  • Knowledge of Fluid & Gas Distribution (OEM) markets is a strong advantage.
  • Familiarity with chromatography is desired.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 28th, 2026
Teen wins $25K for low-cost airborne bacteria sampler at Thermo Fisher Junior Innovators Challenge

Bailey Quinn Frank, 15, of Fort Lauderdale, Florida, won the $25,000 Thermo Fisher Scientific ASCEND Award, the top prize at the 2026 Thermo Fisher Scientific Junior Innovators Challenge. Thermo Fisher Scientific and Society for Science announced the winners in Washington, D.C. Frank built a low-cost environmental DNA sampler that uses a small fan and filter paper to collect airborne bacteria. She says it could help rural communities monitor health threats where resources for disease surveillance are limited. The 30 finalists, chosen from nearly 2,000 applicants, shared more than $100,000 in awards. Four other top winners each received $10,000, including twin brothers Henry and Jack Grover, 14, who developed a hydrogel sprayer to stop wildfires reigniting.

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher shares rise just 1% despite Q3 revenue of $12.14B and higher guidance

Thermo Fisher Scientific shares rose about 1% after the company reported third-quarter 2026 results, a muted reaction to a clean earnings beat. Revenue reached $12.14 billion, up about 9% from $11.12 billion a year earlier, while adjusted earnings per share were $6.68. Net income, excluding extra items, rose about 7% to $1.72 billion. Adjusted operating margin expanded by 120 basis points to 24.5%, and the company raised its full-year earnings guidance. Laboratory Products & Biopharma Services grew 10% organically, with margins up 100 basis points. Organic revenue growth for 2026 is only 4%, and a planned microbiology divestiture will remove $645 million of revenue.

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.